Dr. Cazzell is a highly-trained foot and ankle surgeon who specializes in diabetic limb salvage procedures and advanced wound healing/tissue repair. He has completed 40+ clinical research trials primarily focused on healing leg and foot wounds. His main areas of interest are advanced wound care, limb preservation and traumatic lower extremity reconstruction. He is a Fellow of the American Professional Wound Care Association and Member of the Academy of Physicians in Wound Healing.
Dr. Cazzell currently serves as a Global Key Opinion Leader in the diabetic lower limb/wound healing/tissue repair, Global Products Strategist in the division of plastics & reconstructive surgical services, Global Products Consultant in advanced biologics and regenerative medicine, and Principal Investigator for research studies examining rates of wound healing. He is also the Founder and Chief Medical Officer for Limb Preservation Platform, Inc., one of the world’s leading research sites dedicated to lower extremity salvage and advanced wound healing.
Dr. Shawn M. Cazzell received his B.S. in Biochemistry/Cell Biology with an emphasis in Enzyme Kinetics and Biochemical Techniques, from the University of California, San Diego. He graduated from the California School of Podiatric Medicine, Samuel Merritt University, in Oakland and completed a three-year PM&S 36 foot and ankle surgery residency at St. Mary’s Medical Center. During the last year of his residency program, he had the honor of serving as Chief Resident. After completing his residency, Dr. Cazzell moved to Fresno, where he became part of the foot and ankle team at Kaiser Permanente. His passion for the diabetic lower limb eventually led him to join a vascular surgery group where his main focus was wound care and limb salvage. His patient population has grown to the point where he needed his own fulltime staff and practice, which is now known as Valley Diabetic Foot Center. This has allowed Dr. Cazzell to focus on providing excellent wound care and implementing amputation prevention techniques.
MedWatch Today: Getting back out on the Green
http://www.yourcentralvalley.com/news/getting-back-out-on-the-green/786832013
Curriculum Vitae
SHAWN M. CAZZELL
DrCazzell@LPPresearch.com
HIGHLIGHTS
Global Key Opinion Leader: Diabetic Lower Limb/Diabetic Limb Salvage/Advanced Wound Healing and Tissue Repair
Global Product Strategist, Emerging Markets: LifeNet Health, Division of Plastic and Reconstructive Surgical Services
Global Product Consultant: Advanced Biologics and Regenerative Medicine Technology Corporations
National Investigator/Principal Investigator: Diabetic Lower Limb Randomized Control Trials
National Investigator and Lead Author: Largest Worldwide Randomized Control Trial Utilizing an Acellular Dermal Matrix for Chronic Non-Healing Wounds
Founder and Chief Medical Officer: Limb Preservation Platform, Inc.
EMPLOYMENT
Valley Diabetic Foot Center, Fresno, CA
Diabetic Limb Salvage/Advanced Wound Healing and Tissue Repair/
Peripheral Neuropathy/Onychomycosis/Plantar Fasciitis
February 2018 – Present
6215 North Fresno Street, Suite 108, Fresno, CA 93710
Valley Podiatry & Diabetic Foot Center, Fresno, CA
Diabetic Limb Salvage/Advanced Wound Healing and Tissue Repair/
Peripheral Neuropathy/Onychomycosis/Plantar Fasciitis
August 2016 – February 2018
6215 North Fresno Street, Suite 108, Fresno, CA 93710
Valley Vascular Surgery Associates, Fresno, CA
Diabetic Limb Salvage/Advanced Wound Healing and Tissue Repair/
Peripheral Neuropathy/Onychomycosis/Plantar Fasciitis
January 2013 – July 2016
1247 East Alluvial Avenue, Suite 101, Fresno, CA 93720
2550 Merced Street, Fresno, CA 93721
Limb Preservation Platform, Inc., Fresno, CA
Principle Investigator, Clinical Research Trials Phases I – IV
July 2014 – Present
6215 North Fresno Street, Suite 108, Fresno, CA 93710
1247 East Alluvial Avenue, Suite 102, Fresno, CA 93720
2550 Merced Street, Fresno, CA 93721
Center for Clinical Research, Inc., San Francisco, CA
Principle Investigator, Clinical Research Trials Phases II – IV
December 2012 – July 2014
2299 Post Street, Suite 210, San Francisco, CA 94115
Kaiser Permanente Medical Group, Fresno CA
Attending/Surgical Podiatrist, Department of Podiatry
August 2010 – December 2012
EDUCATION
California School of Podiatric Medicine, Samuel Merritt University, Oakland, CA
Doctor of Podiatric Medicine
May 2007
University of California, San Diego, CA
Bachelor of Science, Biochemistry/Cell Biology, Enzyme Kinetics/Biochemical Techniques
RESIDENCY
St. Mary’s Medical Center PM&S 36
Foot and Ankle Surgery Residency, San Francisco, CA 94117
PGY-I Surgical Internship: July 2007- June 2008
PGY-II/III (Chief) Foot and Ankle Surgery: July 2008- June 2010
PRESENTATIONS
Treatment Methods and Experience Using a Novel Aggregating Powder Dressing, as a Primary Dressing, Over a Single Layer Skin Equivalent. Results presented at the American College of Foot and Ankle Orthopedics and Medicine Scientific Conference, Orlando, FL, July 2009.
A Randomized, Open Label, Controlled Trial of a Tri‐Layer Extracellular Matrix vs. Standard Care in the Healing of Diabetic Foot Ulcers. Results presented at The Symposium on Advanced Wound Care, San Antonio, TX, May 2015.
A Multicenter, Randomized Study to Assess a Sterile, Hydrated Acellular Dermal Matrix Versus Conventional Care Wound Management in Subjects with Venous Stasis Ulcers: An Interim Analysis. Results presented at The Symposium on Advanced Wound Care, San Antonio, TX, May 2015.
A Multicenter, Randomized Study to Assess a Sterile, Hydrated Acellular Dermal Matrix versus Conventional Care Wound Management in Subjects with Venous Stasis Ulcers. Results presented at The Symposium on Advanced Wound Care, Las Vegas, NV, September 2015.
An Evaluation of Tissue Engineering Approaches for Treatment of Neuropathic Diabetic Foot Ulcers (DFUs) Resistant to Standard of Care (SOC): An Interim Analysis of a Prospective, Randomized Controlled Trial. Results presented at The Symposium on Advanced Wound Care, Las Vegas, NV, September 2015.
Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix vs Conventional Wound Care Management and active Comparator in Treatment of Full Thickness Diabetic Foot Ulcers. Results presented at John A. Boswick Burn Symposium, Maui, HI, February 2016
Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix vs Conventional Wound Care Management and active Comparator in Treatment of Full Thickness Diabetic Foot Ulcers. Results presented at Diabetic Limb Salvage Symposium, Georgetown University, Washington, DC, April 2016
Healing Rates in a Multicenter Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix vs Conventional Wound Care Management and active Comparator in Treatment of Full Thickness Diabetic Foot Ulcers. Results Presented at The Symposium on Advanced Wound Care, Atlanta, GA, April 2016
Prospective Study Exploring Use of a Sterile, Room Temperature, Acellular Dermal Matrix* to Treat Chronic Wagner Grade 3 & 4 Diabetic Foot Ulcers. Abstract accepted for presentation at The Symposium on Advanced Wound Care, Charlotte, NC, April 2018.
PUBLICATIONS
Dobbs, B.M., Cazzell, S.M., Dini, M. Central talar dome lesions: a unique surgical approach with incorporation of a talar allograft for joint reconstitution and restoration of function. Journal of the American Podiatric Medical Association. 2011 Mar-Apr; 101(2):192-5.
Cazzell, S.M., Lange, D.L., Dickerson, Jr., J.E., Slade, H.B. The Management of Diabetic Foot Ulcers with Porcine Small Intestine Submucosa Tri-Layer Matrix: A Randomized Controlled Trial. Advances in Wound Care. 2015; 4(12): 711-718.
Walters J., Cazzell S., Pham H., Vayser D., Reyzelman A. Healing rates in a Multi-Center Assessment of a Sterile, Room Temperature, Acellular Dermal Matrix vs. Conventional Care Wound Management and an Active Comparator in the Treatment of Full-thickness Diabetic Foot Ulcers. ePlasty: 2016; 16.
Frykberg R.G., Cazzell S.M., Arroyo-Rivera J., Tallis A., Reyzelman A.M., Saba F., Warren L., Stouch B.C., Gilbert T.W. Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis. Journal of Wound Care. 2016; 25(Sup7): S18-25.
Kirsner, R.S., Vanscheidt, W., Keast, D., Lantis, J.C., Dove, C.R., Cazzell, S.M., Vartivarian, M., Augustin, M., Marston, W.A., McCoy, N.D., Cargill, D.I., Lee, T.D., Dickerson, J., Slade, H. Phase 3 Evaluation of HP802-247 in the Treatment of Chronic Venous Leg Ulcers. Wound Repair and Regeneration. 2016; 24(5): 894-903.
Cazzell, S., Vayser, D., Pham, H., Walters, J., Reyzelman, A., Samsell, B., Dorsch, K., Moore, M. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair and Regeneration. 2017; 25(3): 483-497.
Frykberg, R.G., Gordon, I.L., Reyzelman, A.M., Cazzell, S.M., Fitzgerald, R.H., Rothenberg, G.M., Bloom, J.D., Peterson, B.J., Linders, D.R., Nouvong, A., Najaf, B. Feasibility and Efficacy of a Smart Mat Technology to Predict Development of Diabetic Plantar Ulcers. Diabetes Care. 2017; 40(7): 973-980.
Bianchi, C., Cazzell, S., Vayser, D., Reyzelman, A.M., Doslouglu, H., Tovmassian, G. Epifix VLU Study Group. A Multicenter Randomized Controlled Trial Evaluating the Efficacy of Dehydrated Human Amnion/Chorion Membrane (EpiFix ®) Allograft for the Treatment of Venous Leg Ulcers. International Wound Journal. 2017; DOI: 10.1111/iwj.12843.
Pacaccio, D.J., Cazzell, S.M., Halperin, G.J., Kasper, M.A., Neutel, J.M., O’Carroll, B.D., Reyzelman, A.M. Human placental membrane as a wound cover for chronic diabetic foot ulcers: A prospective, postmarket, CLOSURE study. Journal of Wound Care. 2018; 27(7): S28–S37.
Cazzell, S., Stewart, J., Agnew, P.S., Senatore, J., Walters, J., Murdoch, D., Reyzelman, A., Miller, S. Randomized Controlled Trial of Micronized Dehydrated Human Amnion/Chorion Membrane (dHACM) Injection Compared to Placebo for the Treatment of Plantar Fasciitis. Foot & Ankle International. 2018; DOI: 10.1177/1071100718788549.
Tettelbach W., Cazzell S., Reyzelman A.M., Sigal F., Caporusso J.M., Agnew P.S. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics. International Wound Journal. 2018; 1–11. DOI: 10.1111/iwj.12976.
Tettelbach W., Cazzell S., Sigal F., Caporusso, J.M., Agnew, P.S., Hanft, J., Dove, C.. A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers. International Wound Journal. 2018; 1–9. DOI: 10.1111/iwj.13001
Health Economics for Treatment of Diabetic Foot Ulcers A Cost-Effectiveness Analysis of Eight Skin Substitutes – submitted to Journal of Wound Care
CLINICAL RESEARCH TRIALS
PRINCIPAL INVESTIGATOR FOR: A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED, BLINDED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF A TOPICAL GENTAMICIN-COLLAGEN SPONGE IN COMBINATION WITH SYSTEMIC ANTIBIOTIC THERAPY IN DIABETIC PATIENTS WITH AN INFECTED FOOT ULCER
PRINCIPAL INVESTIGATOR FOR: A PHASE IIB, PROSPECTIVE, SINGLE-BLINDED, RANDOMIZED CONTROLLED TRIAL OF THE MICRONIZED DHACM INJECTION AS COMPARED TO THE SALINE PLACEBO INJECTION IN THE TREATMENT OF PLANTAR FASCIITIS
PRINCIPAL INVESTIGATOR FOR: A MULTICENTER PROSPECTIVE, RANDOMIZED, CONTROLLED, COMPARATIVE PARALLEL STUDY OF DEHYDRATED HUMAN AMNION/CHORION MEMBRANE (DHACM) WOUND GRAFT IN THE MANAGEMENT OF DIABETIC FOOT ULCERS
PRINCIPAL INVESTIGATOR FOR: A PHASE-3 PROSPECTIVE, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF CUREXCELL® AS AN ADJUNCT TO GOOD ULCER CARE MEASURES IN TREATING CHRONIC VENOUS LEG ULCERS
PRINCIPAL INVESTIGATOR FOR: A MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL TRIAL TO ASSESS THE CLINICAL EFFECTIVENESS OF DERMACELL®, CONVENTIONAL CARE WOUND MANAGEMENT, AND GRAFTJACKET® IN SUBJECTS WITH CHRONIC WOUNDS IN THE LOWER EXTREMITIES
PRINCIPAL INVESTIGATOR FOR: AN EVALUATION OF TISSUE ENGINEERING APPROACHES FOR TREATMENT OF NEUROPATHIC DIABETIC FOOT ULCERS RESISTANT TO STANDARD OF CARE: A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL
PRINCIPAL INVESTIGATOR FOR: A PHASE III, MULTINATIONAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, SHAM-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF CUREXCELL® AS AN ADJUNCT TO GOOD WOUND CARE MEASURES IN TREATING LOWER EXTREMITY CHRONIC ULCERS IN ADULTS WITH DIABETES MELLITUS
PRINCIPAL INVESTIGATOR FOR: A PHASE 3 RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED STUDY INVESTIGATING THE SAFETY AND EFFICACY OF HP802-247 IN THE TREATMENT OF VENOUS LEG ULCERS >12 CM2 TO ≤ 36 CM2
PRINCIPAL INVESTIGATOR FOR: A PHASE 3 RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED STUDY INVESTIGATING THE SAFETY AND EFFICACY OF HP802-247 IN THE TREATMENT OF VENOUS LEG ULCERS
PRINCIPAL INVESTIGATOR FOR: A NON-INTERVENTIONAL SAFETY STUDY PROVIDING 12 MONTHS FOLLOW-UP FROM FIRST EXPOSURE TO HP802-247 IN SUBJECTS WITH VENOUS LEG ULCER
PRINCIPAL INVESTIGATOR FOR: A MULTI-CENTER, RANDOMIZED, CONTROLLED CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFECTIVENESS OF INTEGRA® DERMAL REGENERATION TEMPLATE FOR THE TREATMENT OF NEUROPATHIC DIABETIC FOOT ULCERS
PRINCIPAL INVESTIGATOR FOR: IN-BALANCE VLUINFLAMMATION, BACTERIA, & ANGIOGENESIS EFFECTS IN LAUNCHING VENOUS LEG ULCER HEALING
PRINCIPAL INVESTIGATOR FOR: RESTORING EQUILIBRIUM AND WOUND STIMULATION TO PROMOTE HEALING OF NON-HEALING DFUS
PRINCIPAL INVESTIGATOR FOR: A PHASE II, RANDOMIZED, CONTROLLED, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF TOPICALLY APPLIED MEBO® WOUND OINTMENT COMPARED TO STANDARD OF CARE IN SUBJECTS WITH DIABETIC FOOT ULCERS
PRINCIPAL INVESTIGATOR FOR: CLINICAL OUTCOMES ASSOCIATED WITH ENZYMATIC DEBRIDEMENT OF DIABETIC FOOT ULCERS FOR UP TO 12 WEEKS WITH CLOSTRIDIAL COLLAGENASE (SANTYL®) OINTMENT
PRINCIPAL INVESTIGATOR FOR: A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO–CONTROLLED, DOSE RANGE FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAMUSCULAR INJECTION OF HUMAN PLACENTA-DERIVED CELLS (PDA-002) IN SUBJECTS WHO HAVE DIABETIC FOOT ULCER WITH PERIPHERAL ARTERIAL DISEASE
PRINCIPAL INVESTIGATOR FOR: EPIFIX® VS. STANDARD OF CARE IN THE TREATMENT OF VENOUS LEG ULCERS
PRINCIPAL INVESTIGATOR FOR: PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF DSC127 COMPARED WITH VEHICLE AND WITH STANDARD-OF-CARE IN DIABETIC FOOT ULCERS (STRIDE 2)
PRINCIPAL INVESTIGATOR FOR: OPEN-LABEL STUDY IN DIABETIC FOOT ULCERS (DFU), TO EVALUATE SAFETY OF 0.03% DSC127 TOPICAL GEL IN CHRONIC USE (STRIDE 5)
PRINCIPAL INVESTIGATOR FOR: IN-HOME ASSESSMENT OF A SMART FOOT MAT FOR PREVENTION OF DIABETIC FOOT ULCERS
PRINCIPAL INVESTIGATOR FOR: A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND MULTICENTER STUDY COMPARING CONTINUOUS DIFFUSION OF OXYGEN (CDO) THERAPY TO STANDARD MOIST WOUND THERAPY (MWT) IN THE TREATMENT OF DIABETIC FOOT ULCERS
PRINCIPAL INVESTIGATOR FOR: THE NUTECH NUSHIELD AND AFFINITY MEMBRANE PRODUCT EVALUATION FOR THE TREATMENT OF NEUROPATHIC DIABETIC FOOT ULCERS (DFUS)
PRINCIPAL INVESTIGATOR FOR: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, SUPERIORITY, PLACEBO-CONTROLLED PHASE 3 STUDY OF PEXIGANAN CREAM 0.8% APPLIED TWICE DAILY FOR 14 DAYS IN THE TREATMENT OF ADULTS WITH MILD INFECTIONS OF DIABETIC FOOT ULCERS
PRINCIPAL INVESTIGATOR FOR: A RANDOMIZED, PROSPECTIVE, MULTI-CENTER FEASIBILITY STUDY OF APT001 PLASMA/NITRIC OXIDE THERAPY FOR THE TREATMENT OF DIABETIC FOOT ULCERS
PRINICIPAL INVESTIGATOR FOR: A PHASE 1B/2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF ADJUNCTIVE TREATMENT WITH TOPICALLY APPLIED MBN-101 IN SUBJECTS WITH MODERATE TO SEVERE DIABETIC FOOT INFECTION (DFI)
PRINICIPAL INVESTIGATOR FOR: A RANDOMIZED TRIAL COMPARING A DUAL ACTION PNEUMATIC COMPRESSION SYSTEM AGAINST MUTI-LAYER BANDAGING SYSTEM: A NON-INFERIORITY STUDY
PRINCIPAL INVESITGATOR FOR: A PROSPECTIVE TRIAL MEASURING THE CLINICAL OUTCOMES FOR DERMACELL AWM IN CHRONIC WAGNER GRADE 3/4 DIABETIC FOOT ULCERS
PRINCIPAL INVESITGATOR FOR: A POSTMARKET, PROSPECTIVE EVALUATION OF HUMAN PLACENTAL MEMBRANE TISSUE USED A WOUND COVER FOR CHRONIC FOOT ULCERS IN PATIENTS WITH DIABETES
PRINCIPAL INVESTIGATOR FOR: A MUTLICENTER PROSPECTIVE, RANDOMIZED, CONTROLLED, COMPARATIVE PARALLEL STUDY OF DEHYDRATED HUMAN UMBILICAL CORD ALLOGRAFT IN THE MANAGEMENT OF DIABETIC FOOT ULCERS
PRINCIPAL INVESTIGATOR FOR: AN EVALUATION OF BIOVANCE, A DEHYDRATED DECELLULARIZED HUMAN AMNIOTIC MEMBRANCE ALLOGRAFT, IN DIABETIC FOOT ULCERS
PRINCIPAL INVESTIGATOR FOR: A PIVOTAL STUDY OF THE USE OF PLASMA/NITRIC OXIDE THERAPY AS PRODUCED BY THE APT001 PLASMA/NITRIC OXIDE GENERATOR IN ADULT SUBJECTS WITH A DIABETIC FOOT ULCER
PRINCIPAL INVESTIGATOR FOR: A PROSPECTIVE, MULTI-CENTER, RANDOMIZED CONTROLLED TRIAL EVALUATING THE USE OF PRIMATRIX DERMAL REPAIR SCAFFOLD FOR THE MANAGEMENT OF DIABETIC FOOT ULCERS
PRINCIPAL INVESTIGATOR FOR: A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO AND ACTIVE CONTROLLED STUDY TO ASSESS ANALGESIC EFFICACY AND SAFETY OF ASP3662 IN SUBJECTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY
PRINCIPAL INVESTIGATOR FOR: A RANDOMIZED, OPEN LABEL CONTROLLED TRIAL OF OASIS® ULTRA TRI-LAYER MATRIX COMPARED TO STANDARD CARE IN THE HEALING OF DIABETIC FOOT ULCERS
PRINCIPAL INVESTIGATOR FOR: A PHASE III, PROSPECTIVE, DOUBLE-BLINDED, RANDOMIZED CONTROLLED TRIAL OF THE MICRONIZED DHACM INJECTION AS COMPARED TO THE SALINE PLACEBO INJECTION IN THE TREATMENT OF PLANTAR FASCIITIS
PRINCIPAL INVESTIGATOR FOR: A PHASE III, PROSPECTIVE, DOUBLE-BLINDED, RANDOMIZED CONTROLLED TRIAL OF THE MICRONIZED DHACM INJECTION AS COMPARED TO THE SALINE PLACEBO INJECTION IN THE TREATMENT OF ACHILLES TENDONITIS
PRINCIPAL INVESTIGATOR FOR: DOSE-RESPONSE RELATIONSHIP STUDY OF S42909 ON LEG ULCER HEALING AFTER ORAL REPEATED ADMINISTRATION IN PATIENTS WITH ACTIVE VENOUS LEG ULCER: A 10-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROSPECTIVE, INTERNATIONAL, MULTICENTRE, PHASE IIA STUDY
PRINCIPAL INVESTIGATOR FOR: A PROSPECTIVE, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL COMPARING TWO DOSES OF VF001-DP TO PLACEBO AS AN ADJUNCT TO STANDARD CARE IN PATIENTS WITH CHRONIC VENOUS LEG ULCERS
PRINCIPAL INVESTIGATOR FOR: AN OPEN-LABEL TRIAL TO ASSESS THE CLINICAL EFFECTIVENESS OF DERMACELL AWM® IN SUBJECTS WITH CHRONIC VENOUS LEG ULCERS
PRINCIPAL INVESTIGATOR FOR: PRODUCT EVALUATION TO ASSESS EFFICACY OF STERILIZED, DEHYDRATED PLACENTAL ALLOGRAFT IN THE TREATMENT OF DIABETIC FOOT ULCERS
PRINCIPAL INVESTIGATOR FOR: A PROSPECTIVE, MULTI-CENTER, RANDOMIZED, PARALLEL-GROUP STUDY COMPARING AMNIOEXCEL® PLUS PLACENTAL ALLOGRAFT MEMBRANE TO APLIGRAF® BI-LAYERED SKIN SUBSTITUTE AND STANDARD OF CARE PROCEDURES IN THE MANAGEMENT OF DIABETIC FOOT ULCERS
PRINCIPAL INVESTIGATOR FOR: A MULTIPLE-DOSE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DYSPORT FOR THE TREATMENT OF HALLUX ABDUCTO VALGUS
PRINCIPAL INVESTIGATOR FOR: RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF WH-1 OINTMENT FOR THE TREATMENT OF CHRONIC DIABETIC FOOT ULCERS
PRINCIPAL INVESTIGATOR FOR: A MULTICENTER, PROSPECTIVE, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND STUDY PERFORMED TO EVALUATE THE SAFETY AND THE EFFICACY OF ESCHAREX (EX-02 FORMULATION) IN DEBRIDEMENT OF VENOUS LEG ULCERS
HOSPITAL STAFF, WOUND CENTER, AND HYPERBARICS APPOINTMENTS
SAINT AGNES MEDICAL CENTER
CLOVIS COMMUNITY MEDICAL CENTER
COMMUNITY REGIONAL MEDICAL CENTER
FRESNO HEART HOSPITAL
CLOVIS COMMUNITY MEDICAL CENTER, LIMB SALVAGE AND WOUND CARE CENTER
SANTE COMMUNITY PHYSICIANS – WOUND CARE
PROFESSIONAL AFFILIATIONS
American Podiatric Medical Association
California Podiatric Medical Association
American College of Foot and Ankle Surgeons
American College of Foot and Ankle Orthopedics and Medicine
American Professional Wound Care Association
American Academy of Wound Management
Wound Healing Society